Format
Items per page
Sort by

Send to:

Choose Destination

Results: 8

1.

Early Implementation of QbD in Biopharmaceutical Development: A Practical Example.

Zurdo J, Arnell A, Obrezanova O, Smith N, Gómez de la Cuesta R, Gallagher TR, Michael R, Stallwood Y, Ekblad C, Abrahmsén L, Höidén-Guthenberg I.

Biomed Res Int. 2015;2015:605427. Epub 2015 May 17. Review.

2.

Aggregation risk prediction for antibodies and its application to biotherapeutic development.

Obrezanova O, Arnell A, de la Cuesta RG, Berthelot ME, Gallagher TR, Zurdo J, Stallwood Y.

MAbs. 2015;7(2):352-63. doi: 10.1080/19420862.2015.1007828.

PMID:
25760769
3.

Small interfering RNA-mediated knockdown of notch ligands in primary CD4+ T cells and dendritic cells enhances cytokine production.

Stallwood Y, Briend E, Ray KM, Ward GA, Smith BJ, Nye E, Champion BR, McKenzie GJ.

J Immunol. 2006 Jul 15;177(2):885-95.

4.

Cellular Notch responsiveness is defined by phosphoinositide 3-kinase-dependent signals.

McKenzie G, Ward G, Stallwood Y, Briend E, Papadia S, Lennard A, Turner M, Champion B, Hardingham GE.

BMC Cell Biol. 2006 Feb 28;7:10.

5.

Notch: a unique therapeutic target for immunomodulation.

McKenzie GJ, Khan M, Briend E, Stallwood Y, Champion BR.

Expert Opin Ther Targets. 2005 Apr;9(2):395-410. Review.

PMID:
15934923
6.

RNA interference.

Stallwood Y.

Pharmacogenomics. 2005 Jan;6(1):13-6. Review. No abstract available.

PMID:
15723601
7.

Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies.

Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, Seymour LW.

Gene Ther. 2001 Mar;8(5):341-8.

8.

Neutralisation of adenovirus infectivity by ascitic fluid from ovarian cancer patients.

Stallwood Y, Fisher KD, Gallimore PH, Mautner V.

Gene Ther. 2000 Apr;7(8):637-43.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk